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The incidence of dementia is increasing at an alarming rate, and has become a
major public health concern. Alzheimer disease (AD) is the most common form of
dementia and is characterized by progressive cognitive impairment. In addition to classical
neuropathological features such as amyloid plaques and neurofibrillary tangles (NFT),
accumulation of activated immune cells has been documented in the AD brain, suggesting
a contribution of neuroinflammation in the pathogenesis of AD. Besides cognitive
deterioration, non-cognitive symptoms, such as agitation, aggression, depression and
psychosis, are often observed in demented patients, including those with AD, and these
neuropsychological symptoms place a heavy burden on caregivers. These symptoms
often exhibit sudden onset and tend to fluctuate over time, and in many cases, they
are triggered by an infection in peripheral organs, suggesting that inflammation plays an
important role in the pathogenesis of these non-cognitive symptoms. However, there is no
mechanistic explanation for the relationship between inflammation and neuropsychiatric
symptoms. Observations from experimental mouse models indicate that alteration of
brain blood vessels, especially blood-brain barrier (BBB) dysfunction, may contribute to
the relationship. The current review summarizes the results from recent studies on the
relationship between inflammation and AD, while focusing on cerebrovascular alterations,
which might provide an insight into the pathogenesis of cognitive/non-cognitive symptoms
in AD patients and suggest a basis for the development of new therapeutic treatments for
these conditions.
Keywords: systemic inflammation, blood-brain barrier, Alzheimer disease, pathogenesis, therapy
INTRODUCTION
Alzheimer disease (AD) is the most common form of demen-
tia, accounting for around 60–90% of all cases (Thies and
Bleiler, 2013), and its incidence is increasing at an alarming
rate all over the world. AD is characterized by progressive
cognitive and behavioral impairment, and cerebral deposition
of senile plaques (extracellular accumulation of beta-amyloid
(Aβ) peptide) and neurofibrillary tangles (NFTs, intracellular
accumulation of hyperphosphorylated tau protein) are unique
neuropathological hallmarks of the disease (Hardy and Selkoe,
2002; Iqbal and Grundke-Iqbal, 2006). Multiple so-called
“disease-modifying” therapies for AD, such as immunother-
apy against Aβ, are now under investigation and have been
tested in clinical trials; however, most of them have had
little success so far (Salloway et al., 2008; Delrieu et al.,
2012; Thies and Bleiler, 2013). There is an urgent need
to identify novel targets to develop alternative therapeutic
strategies.
There is a growing body of evidence linking inflammation and
the pathogenesis of AD (Akiyama et al., 2000; Lee et al., 2010;
Holmes and Butchart, 2011). Microglia, which play a critical role
in the brain immune system, are known to be activated in the
AD brain, and clusters of reactive microglia are found associated
with amyloid plaque (Serrano-Pozo et al., 2013). Recently, it has
been reported that CD33, which regulates the innate immune
system, as well as its gene, has been shown to be a risk factor
for AD, CD33 inhibits clearance of Aβ by microglia, and deletion
of CD33 in an Alzheimer transgenic mouse significantly reduced
pathological amyloid in the brain (Bradshaw et al., 2013; Griciuc
et al., 2013). Although the role of neuroinflammation in the
AD brain remains unclear, findings from experimental disease
models and clinical studies have demonstrated a significant con-
tribution of inflammation to pathological features and symptoms
of AD.
On the other hand, recent epidemiological studies have
provided direct evidence linking AD and vascular risk
factors such as hypertension and diabetes mellitus, which
is now attracting attention (Takeda et al., 2008; Sato et al.,
2011; Sato and Morishita, 2013). Also, it is well recognized
that the pathogenesis of AD and vascular dementia overlap
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(Iadecola, 2010, 2013; Muresanu et al., 2014). Cerebrovascular
alteration, which is a common pathological change in these
diseases, is a possible mechanism of this relationship. Our
recent studies using unique AD mouse models showed that
cerebrovascular inflammation induced by a diabetic condition
(Takeda et al., 2010) or peripheral inflammation (Takeda et al.,
2013) had a significant impact on pathological features of
the AD brain and cognitive/non-cognitive symptoms of the
animals.
In this review, we discuss recent findings on the relationship
between inflammation and AD, focusing on cerebrovascular alter-
ations, which might provide a new insight into the pathogenesis of
AD and a basis for the development of an alternative therapeutic
strategy for the disease.
AD NEUROPATHOLOGY AND INFLAMMATION
In addition to classical neuropathological signs like amyloid
plaques and NFT, significant accumulation and infiltration of
activated immune cells have been well documented in the AD
brain (Dickson et al., 1993; Akiyama et al., 2000; Letiembre et al.,
2009), suggesting a contribution of neuroinflammation to AD
pathogenesis. Clustering of activated microglia (Haga et al., 1989;
Simard et al., 2006) and astrocytes (Mrak et al., 1996) around
amyloid plaques is observed in the AD brain, associated with
upregulated expression of a variety of inflammatory cytokines,
including interleukin (IL)-1 (Griffin et al., 1995), IL-6 (Bauer
et al., 1991), tumor necrosis factor-α (TNF-α; Tarkowski et al.,
1999), and transforming growth factor-β (TGF-β; van der Wal
et al., 1993). It has been shown that innate immune receptors,
such as toll-like receptor and lipopolysaccharide (LPS) receptor
(CD14), are upregulated in the human AD brain (Letiembre
et al., 2009). Furthermore, it is well known that most of the
AD transgenic mouse models exhibit significant enhancement
of neuroinflammation around amyloid plaques, like those in
the human AD brain (Frautschy et al., 1998; Matsuoka et al.,
2001; Janelsins et al., 2005), and its severity increases with pro-
gression of pathological amyloid with age (Sheng et al., 2000).
Importantly, some markers of glial activation are elevated even
before the development of amyloid deposition, implying that neu-
roinflammation precedes typical AD neuropathological changes
and has some causative effect in AD pathogenesis (Sheng et al.,
2000). Recent high-resolution positron emission tomographic
(PET) imaging has enabled longitudinal observation of amy-
loid accumulation and associated microglial activation in the
Alzheimer amyloid precursor protein (APP) transgenic mouse,
and demonstrated a dynamic change in microglial activity in
response to anti-amyloid therapy (Maeda et al., 2007; Ji et al.,
2008).
However, whether activation of the local immune system in the
diseased brain is the cause or consequence of AD, and whether
it is causes a positive or negative effect on disease progression
remain controversial. It has been reported that direct injection
of IL-1 into the rodent brain upregulates beta-APP, supporting
the idea that overexpression of IL-1 in the brain could be a
driving force in AD pathogenesis (Sheng et al., 1996). Craft et al.
(2005) reported that IL-1 receptor antagonist knockout mice,
which have enhanced IL-1 signaling, show increased vulnerability
to Aβ-related toxicity, suggesting that enhanced neuroinflam-
mation mediated by IL-1 could have an unfavorable effect on
the AD brain. On the other hand, Shaftel et al. (2007) have
shown that local overexpression of IL-1β in the hippocampus
of an APP transgenic mouse model significantly decreased the
severity of pathological amyloid, demonstrating a possible adap-
tive role of IL-1β in AD pathogenesis. Similarly, an APP trans-
genic mouse model overexpressing IL-6 in the brain showed
attenuated Aβ deposition associated with enhanced gliosis, indi-
cating that IL-6-mediated gliosis could have a favorable effect
in terms of clearing Aβ from the brain (Chakrabarty et al.,
2010). However, Ghosh et al. (2013) also reported that sus-
tained IL-1β overexpression exacerbated pathological tau despite
reduced Aβ burden in an AD mouse model. These conflicting
findings suggest a complex role of inflammation in the AD
brain.
Along the same line, the therapeutic effect of anti-
inflammatory drugs on human AD patients is still controversial
(McGeer et al., 1996). Findings from experimental studies using
mouse model have shown favorable effects of anti-inflammatory
agents such as nonsteroidal anti-inflammatory drugs (NSAIDs)
on AD neuropathological features and cognitive disturbance
(Lim et al., 2000, 2001; Yan et al., 2003). However, clinical
trials of traditional anti-inflammatory drugs, including NSAIDs
(Breitner et al., 1994; Rich et al., 1995) and cyclooxygenase
(COX) inhibitors (McGeer, 2000; Trepanier and Milgram, 2010),
have failed to demonstrate their positive effect on AD patients
(Rogers et al., 1993; Scharf et al., 1999; Aisen et al., 2003; Reines
et al., 2004), though it has been claimed that they have lower
accessibility into the brain.
SYSTEMIC INFLAMMATION AND AD
The brain has been considered to be an “immune-privileged”
organ, isolated from the peripheral immune system (Shrestha
et al., 2013). However, recent evidence shows that there is bi-
directional communication between the brain and the peripheral
immune system (Holmes and Butchart, 2011). A neural route
via the vagal nerve, circumventricular organs that lack a blood-
brain barrier (BBB), direct entry of monocytes through the
BBB, and inflammatory lipid mediators such as prostaglandins
that can cross the BBB are recognized to be important com-
munication pathways connecting the brain and the systemic
immune system (Quan and Banks, 2007). Alteration of peripheral
immune activity can affect the brain immune system through
these pathways. In the AD brain, the BBB becomes leaky due
to damage from accumulation of Aβ along brain blood ves-
sels (cerebral amyloid angiopathy, CAA) and associated vas-
cular inflammation (Greenberg et al., 2004; Kinnecom et al.,
2007), which could alter communication between the brain and
the peripheral immune system. Activated peripheral immune
cells that enter the brain though the leaky BBB may directly
or indirectly affect the central nervous immune system and
modulate the pathogenesis of AD. Indeed, Dunn et al. (2005)
reported an association between systemic inflammation and
increased risk of dementia in a case-control study. Although
clinical evidence linking the risk of developing AD and systemic
inflammation is still limited and controversial (Sundelof et al.,
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2009), some observational studies and a meta-analysis showed
that elevated peripheral inflammatory markers are associated
with increased risk of overall dementia (Koyama et al., 2013),
suggesting a positive correlation between systemic inflammation
and neurodegeneration.
This interaction between the peripheral immune system and
the brain might provide a possible explanation for the linkage of
some chronic diseases like hypertension in midlife and diabetes,
in which persistent inflammation plays a significant role in their
pathogenesis, with increased risk of dementia including AD.
INFLAMMATION AND DEMENTIA-ASSOCIATED
BEHAVIORAL DISTURBANCE
Non-cognitive symptoms, such as agitation, aggression, depres-
sion and psychosis, are often observed in demented patients
including those with AD, in addition to progressive cognitive
deterioration. These symptoms, known as “behavioral and psy-
chological symptoms of dementia” (BPSD), have been reported
to occur in about 20% of AD patients (Lyketsos et al., 2000)
and affect up to 80% of patients living in social care facil-
ities and nursing homes (Margallo-Lana et al., 2001; Ryu
et al., 2005), placing an extremely heavy burden on fami-
lies and caregivers (Corbett et al., 2012; Ballard and Corbett,
2013). These neuropsychological symptoms often exhibit sud-
den onset and tend to fluctuate over time. In many cases,
they are triggered by an acute change in the patient’s phys-
ical condition such as dehydration, pain, or exacerbation of
an existing chronic health condition. Infection in peripheral
organs, such as pneumonia or urinary tract infection, is often
associated with manifestation of BPSD (Holmes and Butchart,
2011), suggesting that inflammation could play an important
role in the pathogenesis underlying these dementia-associated
behavioral disturbances. Importantly, severe neuropsychological
symptoms triggered by peripheral infection can develop with-
out direct bacterial invasion into the brain spreading from
peripheral organs (van Gool et al., 2010) and without signs
of sepsis (Ebersoldt et al., 2007). A prospective matched con-
trol study has shown a strong association between dementia
and postoperative delirium in elderly people who underwent
hip surgery, suggesting a link between systemic inflammation
induced by peripheral intervention and dementia-associated
psychiatric symptoms (Kat et al., 2008). However, at present,
specific mechanisms for the susceptibility of demented patients to
infection-triggered neuropsychological symptoms have not been
proposed.
Some experimental findings using animal models have sug-
gested possible mechanisms for the effect of systemic infection
on behavioral disturbance. Acute and chronic infusion of LPS
into the rat brain impaired the function of cholinergic neurons,
which is essential for maintaining healthy brain function, asso-
ciated with accumulation of reactive astrocytes and microglia
within the basal forebrain (Willard et al., 1999). Godbout et al.
reported that LPS-induced peripheral inflammation caused more
severe neuroinflammation and associated behavioral disturbances
in elderly mice compared to young mice, which indicates that
an age-related potential augmentation of neuroinflammatory
response might affect the susceptibility to behavioral problems
following activation of the peripheral immune system (Godbout
et al., 2005; Godbout and Johnson, 2009). The Alzheimer APP
transgenic mouse is known to develop a variety of behavioral
problems such as diurnal rhythm disturbance and increased
aggression resembling BPSD in demented patients (Vloeberghs
et al., 2004, 2007), which could be a valuable tool for investigating
more specific mechanisms of the neuropsychological symptoms
in AD.
BLOOD-BRAIN BARRIER, CEREBROVASCULAR FUNCTION
AND NEURODEGENERATIVE DISEASES
The entry of most molecules into the central nervous system from
the peripheral circulation is strictly regulated by the BBB, and
its function and integrity are maintained by the “neurovascular
unit”, which is composed of vascular endothelial cells, astrocytes,
pericytes (Hall et al., 2014), and neurons (Bell and Zlokovic,
2009; Neuwelt et al., 2011; Zlokovic, 2011). Brain endothelial
cells lining cerebral microvessels act as a physical barrier because
they are sealed together by tight junctions, resulting in limited
paracellular diffusion, and they have no fenestrations, in contrast
to leaky vessels in peripheral organs (Abbott et al., 2006; Ricci
et al., 2006). These endothelial cells are surrounded by a basal
lamina and the endfeet of astrocytes, which contribute to BBB
function and integrity by regulating expression levels of tight
junction molecules (Dehouck et al., 1990) and specific trans-
porters (McAllister et al., 2001). Interactions between endothelial
and astroglial cells at the BBB play an important role in maintain-
ing proper brain function by regulating regional cerebral blood
flow and metabolism, which could affect local neuronal function
(Abbott et al., 2006).
There is emerging evidence that BBB dysfunction is associated
with the pathogenesis of a variety of neurodegenerative disorders
such as AD (Bell and Zlokovic, 2009; Zlokovic, 2011), Parkinson
disease (Chung et al., 2010; Bartels, 2011), multiple sclerosis
(Lassmann et al., 2012; Prineas and Parratt, 2012; Tourdias and
Dousset, 2013), and amyotrophic lateral sclerosis (Rodrigues
et al., 2012; Garbuzova-Davis and Sanberg, 2014; Winkler et al.,
2014), in addition to typical cerebrovascular disorders such as
stroke and vascular dementia (Wardlaw et al., 2003; Iadecola,
2013).
It has become recognized that there is significant overlap
between the pathogenesis of AD and that of vascular dementia.
The results of recent epidemiological studies have shown that
vascular risk factors such as hypertension (Skoog and Gustafson,
2003), diabetes mellitus (Ott et al., 1999; Sato et al., 2011) and
atherosclerosis (Takeda et al., 2008) have a significant impact
on the progression of AD, although the mechanisms under-
lying these interactions remain unclear. One of the possible
explanations for this association is that cerebrovascular damage
caused by these diseases could affect cognitive function. Gentile
et al. (2009) examined the effect of hypertension on pathological
amyloid in the brain using two mouse models of hypertension,
demonstrating Aβ deposition in the hypertensive mouse brain
which was associated with impairment of BBB integrity. It has
been reported that some antihypertensive drugs restored cere-
brovascular dysfunction via reduction of oxidative stress and
improved cognitive function in an AD mouse model (Takeda
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et al., 2009). Our previous study demonstrated that, using unique
diabetic AD mouse models, co-existence of a diabetic condi-
tion could accelerate Aβ-related vascular alterations via increased
expression of inflammatory cytokines, which was associated with
induction of the receptor for advanced glycation end products
(RAGE) in the cerebral vasculature (Takeda et al., 2010). These
findings imply that cerebrovascular dysfunction plays a role not
only in vascular dementia but also in the AD brain with non-
genetic risk factors.
ApoE-ε4 is a strong genetic risk factor for sporadic AD; how-
ever, how it impacts on AD pathogenesis is still unknown (Bu,
2009). The APOE-ε4 allele increases the accumulation of senile
plaques in AD patients as well as in cognitively normal people
(Reiman et al., 2009; Morris et al., 2010). One recent report
has shown that ApoE also regulates cerebrovascular function via
the cyclophilin A (CypA)-nuclear factor-κB (NF-κB)—matrix-
metalloproteinase-9 (MMP9) pathway in pericytes in an isoform-
specific manner, and that CypA could be a target for treating
ApoE-ε4-mediated neurovascular impairment and the related
neuronal malfunction (Bell et al., 2012). This observation could
provide a new insight for understanding the cerebrovascular-
related pathogenesis of AD, linking the contribution of ApoE-ε4
as a risk factor.
BBB FUNCTION IN ALZHEIMER BRAIN
Some studies have shown that BBB integrity is compromised in
Alzheimer APP transgenic mice even before they develop amyloid
plaques and cognitive impairment. Ujiie et al. (2003) examined
BBB integrity in the Tg2576 AD mouse model using a well-
established method based on dye leakage, and found that AD
mice exhibit breakdown of the BBB as early as 4 months of
age, which is much earlier than the manifestation of amyloid
plaque deposition and cognitive dysfunction. This observation
implies that functional alteration of the BBB could be one of the
earliest signs of AD. Along the same line, Dickstein et al. (2006)
demonstrated that Aβ immunization therapy could restore BBB
integrity in the same AD mouse model (Tg2576), in addition
to improvement of typical AD brain pathological features such
as plaque burden and microgliosis, suggesting a new strategy
for AD treatment focusing on BBB function (Dickstein et al.,
2006). However, we need to give careful consideration to the
effect of Aβ immunization on BBB function because it has also
been demonstrated that passive immunization with Aβ antibodies
resulted in a significant increase in both the frequency and severity
of CAA-related microhemorrhages in different APP transgenic
mouse models (Pfeifer et al., 2002; Racke et al., 2005; Burbach
et al., 2007; Luo et al., 2010).
Our recent study has shown that, using an Alzheimer APP
transgenic mouse, peripheral inflammation could be more likely
to spread into the brain due to increased vulnerability of the
blood-brain-barrier to peripherally evoked inflammation, leading
to more severe non-cognitive symptoms (Takeda et al., 2013).
After peripheral injection of LPS to induce systemic inflam-
mation, APP transgenic mice showed a greater increase in
inflammatory cytokine levels in brain interstitial fluid and more
severe non-cognitive symptoms (such as attenuation of basal
activity, social interaction behavior, and food intake) compared
to wild-type control animals, while there was no difference in
inflammatory cytokine levels in plasma and peripheral organs
between genotypes. The BBB became leaky in the AD trans-
genic mouse brain during the course of inflammation, suggesting
increased vulnerability of the BBB to systemic inflammation in
the AD mouse brain, which might be a mechanism for peripheral
inflammation spreading more easily to the brain. Importantly,
no clear change in brain Aβ level was observed after peripheral
administration of LPS, meaning that the behavioral symptoms
induced by peripherally evoked inflammation may not be due to
change in brain Aβ level. These findings indicate that the potential
vulnerability of the BBB to inflammation underlies the increased
severity of behavioral impairment in AD.
The detailed mechanisms of BBB breakdown during sys-
temic inflammation in the AD mouse brain remain unclear
and need to be elucidated in order to tackle this pathologi-
cal event. The relationship between Aβ and endothelial cells
has been under extensive investigation and there is substantial
evidence that Aβ could alter endothelial function, which plays
a critical role in BBB integrity (Suhara et al., 2003; Vagnucci
and Li, 2003; Hayashi et al., 2009; Takeda et al., 2009). It has
been demonstrated in vitro that intracellular Aβ42 could be
toxic to endothelial cells via disruption of the Akt/glycogen syn-
thase kinase (GSK)-3β pathway (Suhara et al., 2003). Hayashi
et al. (2009) also reported that Aβ40 altered endothelial func-
tion and impaired vascular regeneration through the induction
of autophagy. Another report showed that oxidative stress was
increased in brain blood vessels of an APP transgenic mouse
(APP23 mouse) even before the manifestation of amyloid plaques
and CAA (Takeda et al., 2009). These changes in the cerebral
vasculature might potentially increase the vulnerability of the BBB
in the AD brain.
SUMMARY
A growing body of evidence links systemic inflammation and
AD pathogenesis in the brain. Although the overall impact of
the activated brain immune system on AD pathological features
is complicated and still controversial, it is clear that it could be
affected by the peripheral immune system. Direct or indirect
modulation of the brain immune system from the periphery
could be a new strategy to alter AD progression. The cerebral
vasculature, especially the BBB, is an important interface linking
peripheral inflammation and the AD brain (Figure 1). It remains
unclear how exactly systemic inflammation could damage the
integrity and function of the BBB and alter cognitive function,
and the mechanisms need to be elucidated in order to develop
new treatments for AD focusing on vascular and other interface
pathology.
Moreover, there is a clear cause-and-effect relationship
between activated systemic inflammation and the development
of neuropsychiatric symptoms in AD, although no mechanistic
explanation for the relationship exists thus far. Furthermore,
to date, there is no alternative treatment for non-cognitive
symptoms of dementia directed against specific pathological
mechanisms. Inflammation-related cerebrovascular alterations
such as BBB breakdown could be a potential target for new
therapies tackling those symptoms.
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FIGURE 1 | Neuropathological features, inflammation, and
cognitive/non-cognitive symptoms of Alzheimer disease. Cerebral
accumulation of amyloid plaques and neurofibrillary tangles (NFT) leads to
neurodegeneration in the AD brain, which causes progressive cognitive
dysfunction such as memory loss and language problems. Non-cognitive
symptoms, such as agitation, aggression and psychosis, are often
observed in AD patients, besides cognitive deterioration. These
symptoms can be triggered by an infection in peripheral organs such as
pneumonia, suggesting a contribution of peripheral inflammation. BBB,
blood-brain barrier.
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